Phase 2
Completed N=10
Creatine Safety & Tolerability in Huntington's Disease
Huntington's Disease (HD)
Source: ClinicalTrials.gov NCT01412151 ↗
Enrolled (actual)
10
Serious AEs
40.0%
Results posted
Dec 2012
Primary outcomePrimary: Tolerability — 5 Participants
Summary
The purpose of this study is to extend findings from the creatine dose-finding study (CREST-UP1) in Huntington's disease to evaluate the long-term safety, tolerability, and clinical impact of high dose creatine.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tolerability |
5 | — |
| SECONDARY Clinical Measures Resources Not Available to Complete Secondary Analyses. |
— | — |
| SECONDARY Biological Markers of Disease Progression |
— | — |
Eligibility Criteria
Inclusion Criteria
- Individuals who have completed the CREST-UP1 study.
- Individuals who are able to take oral medication.
- Individuals capable of providing informed consent and complying with trial procedures.
Exclusion Criteria
- History of known sensitivity or intolerability to creatine.
- Clinical evidence of unstable medical illness in the investigator's judgment.
Additional eligibility criteria apply.
Data sourced from ClinicalTrials.gov (NCT01412151). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.